Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30
LONDON and SALT LAKE CITY, March 22, 2023 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that it will report its second quarter and first half fiscal year 2023 financial results on Thursday, March 30, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).
Conference Call Details:
To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.
Webcast Registration link:
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
For further information, please contact:
|James McCullough, CEO||Via Walbrook PR|
|Stifel (Nominated Adviser, Joint Broker)||Tel: 020 7710 7600|
|Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea|
|Investec Bank plc (Joint Broker)||Tel: 020 7597 4000|
|Gary Clarence / Shalin Bhamra|
|Walbrook PR Limited||Tel: 020 7933 8780 or email@example.com|
|Paul McManus / Lianne Applegarth||Mob: 07980 541 893 / 07584 391 303|
|Peter DeNardo||Tel: 415-389-6400 or firstname.lastname@example.org|